Bicycle Therapeutics has filed to raise up to $86 million in a Nasdaq IPO. The British biotech wants the money to prepare for phase 2 and 3 clinical trials of its lead anticancer candidate, BT1718. BT1718, like the rest of Bicycle’s pipeline, is based on a type of fully synthetic short peptide the company calls “Bicycles.” Source: Fierce Biotech 29/4/2019